surpass 2 tirzepatide In patients with type diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT Effect of tirzepatide versus insulin

Discover what these leading brands have to offer for your practice

*Oral Diseases*, 22(6), 463-493

Its commercialization for human therapeutic use remains prohibited in France, Europe, and the United States strict research use

Breast Cancer: A 3047% Risk Reduction Among the most clinically significant findings was a real-world cohort study presented at ASCO 2026, which reported that women with Type 2 diabetes or obesity using GLP-1 receptor agonists experienced a 30 to 47% reduction in breast cancer risk compared to non-users

Explore the benefits, side effects, and the debate between oral precursors versus expensive infusions

Breaking up sedentary time with light movement improves metabolic health and reduces the risk of central obesity